Literature DB >> 17822464

A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis.

Kenneth M Peters1, Kevin M Feber, Richard C Bennett.   

Abstract

OBJECTIVE: To compare sacral nerve stimulation (SNS) with pudendal nerve stimulation (PNS) for interstitial cystitis (IC). PATIENTS AND METHODS: Twenty-two patients with well-documented, refractory IC had a tined lead placed at S3 and a second electrode implanted at the pudendal nerve via a posterior approach. In a blinded, randomized design, each lead was tested for 7 days. The best lead was implanted to a pulse generator and patients were followed at 1, 3 and 6 months.
RESULTS: The time required to place a sacral lead was 27.4 min, and a pudendal lead 19.6 min (P = 0.039). Of the 22 patients, 17 (77%) responded and had a permanent implant placed. PNS was chosen as the better lead in 77% and SNS in 24%. The order in which the lead was stimulated had no effect on the final lead implanted and there was no 'carry-over' effect. The overall reduction in symptoms was 59% for PNS and 44% for SNS (P = 0.05). At 6 months after implantation, voids improved by 41% (PNS) and 33% (SNS), and mean voided volume increased 95% and 21%, respectively; validated IC questionnaires improved markedly and complications were minimal.
CONCLUSIONS: This is the first 'blinded' study of SNS vs PNS for IC. A pudendal lead was implanted successfully in all patients, and most chose PNS as better than SNS; the improvement was sustained over time.

Entities:  

Mesh:

Year:  2007        PMID: 17822464     DOI: 10.1111/j.1464-410X.2007.07082.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  40 in total

1.  Analgesic effect of bilateral ultrasound-guided pudendal nerve blocks in management of interstitial cystitis.

Authors:  Lyn Li Lean; Dominic Hegarty; Dominic Harmon
Journal:  J Anesth       Date:  2012-02       Impact factor: 2.078

Review 2.  Alternative approaches to sacral nerve stimulation.

Authors:  Kenneth M Peters
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

3.  Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats.

Authors:  Changfeng Tai; Bing Shen; Mang Chen; Jicheng Wang; James R Roppolo; William C de Groat
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-24

4.  First experiences with pudendal nerve stimulation in fecal incontinence: a technical report.

Authors:  S Bock; P Folie; K Wolff; L Marti; D S Engeler; F H Hetzer
Journal:  Tech Coloproctol       Date:  2010-03       Impact factor: 3.781

5.  A pilot study of chronic pudendal nerve stimulation for faecal incontinence for those who have failed sacral nerve stimulation.

Authors:  G P Thomas; A T George; T C Dudding; R J Nicholls; C J Vaizey
Journal:  Tech Coloproctol       Date:  2014-06-22       Impact factor: 3.781

Review 6.  Interstitial cystitis/bladder pain syndrome: diagnosis and management.

Authors:  I Offiah; S B McMahon; B A O'Reilly
Journal:  Int Urogynecol J       Date:  2013-02-22       Impact factor: 2.894

7.  Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.

Authors:  Mari Imamura; Neil W Scott; Sheila A Wallace; Joseph A Ogah; Abigail A Ford; Yann A Dubos; Miriam Brazzelli
Journal:  Cochrane Database Syst Rev       Date:  2020-07-30

8.  [Chronic pelvic pain syndrome: neurostimulation, neuromodulation and acupuncture].

Authors:  M Walter; U Sammer; T M Kessler
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

9.  Battery explantation after sacral neuromodulation in the Medicare population.

Authors:  Anne P Cameron; Jennifer T Anger; Rodger Madison; Christopher S Saigal; J Quentin Clemens
Journal:  Neurourol Urodyn       Date:  2012-07-27       Impact factor: 2.696

Review 10.  Neuromodulation in male chronic pelvic pain syndrome: rationale and practice.

Authors:  Claire C Yang
Journal:  World J Urol       Date:  2013-04-26       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.